Oncogenic roles of the lncRNA LINC00460 in human cancers

Clear cell Renal Cell Carcinoma (ccRCC), the most deadly and life-threatening tumor in the urinary system, has a dismal prognosis and a high risk of metastasizing. Regulation of ferroptosis is a prospective therapeutic target to eradicate malignant cells. Our objective was to seek ferroptosis-associated long non-coding RNAs (FALs) and developed a prediction signature for ccRCC. We extracted transcriptome data and clinical information from The Cancer Genome Atlas (TCGA) databases. Ferroptosis-associated genes (FAGs) were obtained from FerrDb database. A ferroptosis-associated lncRNA prognostic signature (FLPS) of ccRCC was generated utilizing univariate Cox regression, least absolute shrinkage and selection operator (LASSO), and multivariate Cox regression, sequentially, based on 8 lncRNAs (LINC00460, AC124854.1, AC084876.1, IGFL2-AS1, LINC00551, AC083967.1, AC073487.1, and LINC02446). The signature's independent predictive value for ccRCC was demonstrated using univariate and multivariate regression analysis (P < 0.05). Subsequently, by combining independent predictive factors, a prognostic nomogram was established. Immunity analysis proclaimed a striking difference in terms of cells, function, checkpoints, and ESTIMATE scores between low- and high-risk groups. Overall, the innovative signature of ferroptosis-associated signatures may have a considerable effect on the immune response and prognosis for ccRCC.

Section: Development and Verification Of Prognosis Flpsmentioning

confidence: 99%

Ferroptosis-associated lncRNA prognostic signature predicts prognosis and immune response in clear cell renal cell carcinoma

Lai

Miao

Ran

2023

“…LINC00460 is an intergenic lncRNA, located on chromosome 13q33.2, which has been previously described in human malignancies 16 . It contains two annotated transcripts, partially sharing the first exon: a shorter one containing three exons made up of 1′746 nucleotides and a longer one of seven exons made up of 2′124 nucleotides base pairs, mainly expressed in normal brain tissue (Suppl.…”

Section: Resultsmentioning

confidence: 99%

Cell type specific long non-coding RNA targets identified by integrative analysis of single-cell and bulk colorectal cancer transcriptomes

Mihaljevic,

Rubin,

Chouvardas

et al. 2024

Long non-coding RNAs (lncRNAs) represent an emerging class of genes which play significant and diverse roles in human cancers. Nevertheless, the functional repertoires of lncRNAs in cancer cell subtypes remains unknown since most studies are focused on protein coding genes. Here, we explored the contribution of lncRNAs in Colorectal Cancer (CRC) heterogeneity. We analyzed 49′436 single-cells from 29 CRC patients and showed that lncRNAs are significantly more cell type specific compared to protein-coding genes. We identified 996 lncRNAs strongly enriched in epithelial cells. Among these, 98 were found to be differentially expressed in tumor samples compared to normal controls, when integrating 270 bulk CRC profiles. We validated the upregulation of two of them (CASC19 and LINC00460) in CRC cell lines and showed their involvement in CRC proliferation by CRISPR-Cas9 knock down experiments. This study highlights a list of novel RNA targets for potential CRC therapeutics, substantiated through experimental validation.

“…LINC00892 has the potential as a biomarker of metastasis in T1 LUAD 50 . LINC00460 is upregulated in the LUAD group and played an important role in the control of oncogenes and tumor suppressors 51 . LINC01281 is downregulated in the LUAD group and therefore may be a prognostic factor for patients with LUAD 52 .…”

Section: Discussionmentioning

confidence: 99%

Machine learning-based integration develops an immunogenic cell death-derived lncRNA signature for predicting prognosis and immunotherapy response in lung adenocarcinoma

Sun,

Guo,

Zhang

et al. 2024

Accumulating evidence demonstrates that lncRNAs are involved in the regulation of the immune microenvironment and early tumor development. Immunogenic cell death occurs mainly through the release or increase of tumor-associated antigen and tumor-specific antigen, exposing “danger signals” to stimulate the body’s immune response. Given the recent development of immunotherapy in lung adenocarcinoma, we explored the role of tumor immunogenic cell death-related lncRNAs in lung adenocarcinoma for prognosis and immunotherapy benefit, which has never been uncovered yet. Based on the lung adenocarcinoma cohorts from the TCGA database and GEO database, the study developed the immunogenic cell death index signature by several machine learning algorithms and then validated the signature for prognosis and immunotherapy benefit of lung adenocarcinoma patients, which had a more stable performance compared with published signatures in predicting the prognosis, and demonstrated predictive value for benefiting from immunotherapy in multiple cohorts of multiple cancers, and also guided the utilization of chemotherapy drugs.